 Hemophilia B
"Hemophilia B" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A deficiency of blood coagulation factor IX inherited as an X-linked disorder. (Also known as Christmas Disease, after the first patient studied in detail, not the holy day.) Historical and clinical features resemble those in classic hemophilia (HEMOPHILIA A), but patients present with fewer symptoms. Severity of bleeding is usually similar in members of a single family. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma. Treatment is similar to that for hemophilia A. (From Cecil Textbook of Medicine, 19th ed, p1008)
| Descriptor ID |
D002836
|
| MeSH Number(s) |
C15.378.100.100.510 C15.378.100.141.510 C15.378.463.510 C16.320.099.510 C16.320.322.235
|
| Concept/Terms |
Hemophilia B- Hemophilia B
- Bs, Hemophilia
- Hemophilia Bs
- Deficiency, Factor IX
- Deficiencies, Factor IX
- Factor IX Deficiencies
- Factor IX Deficiency
- Hemophilia B Leyden
- Hemophilia B(M)
- Hemophilia Bs (M)
- Plasma Thromboplastin Component Deficiency
- F9 Deficiency
- Deficiencies, F9
- Deficiency, F9
- F9 Deficiencies
- Christmas Disease
- Disease, Christmas
- Haemophilia B
- Haemophilia Bs
|
Below are MeSH descriptors whose meaning is more general than "Hemophilia B".
Below are MeSH descriptors whose meaning is more specific than "Hemophilia B".
This graph shows the total number of publications written about "Hemophilia B" by people in this website by year, and whether "Hemophilia B" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 2 | 0 | 2 | | 1998 | 1 | 0 | 1 | | 1999 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2003 | 3 | 0 | 3 | | 2006 | 1 | 0 | 1 | | 2007 | 2 | 0 | 2 | | 2010 | 1 | 0 | 1 | | 2013 | 2 | 0 | 2 | | 2014 | 1 | 0 | 1 | | 2016 | 2 | 0 | 2 | | 2017 | 2 | 0 | 2 | | 2018 | 5 | 1 | 6 | | 2019 | 2 | 0 | 2 | | 2021 | 6 | 0 | 6 | | 2022 | 1 | 0 | 1 | | 2023 | 2 | 1 | 3 | | 2024 | 2 | 2 | 4 | | 2025 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Hemophilia B" by people in Profiles.
-
Buckner TW, Kessler C, Castaman G, Hermans C, Jiménez-Yuste V, Mahlangu J, Miesbach W, Oldenburg J, Recht M, Valentino LA, Wheeler AP, Pipe SW. Pain Reduction Following Eptacog Beta Treatment of Bleeding Episodes in Adolescents and Adults With Haemophilia A or B Complicated by Inhibitors. Haemophilia. 2025 Jul; 31(4):713-721.
-
Wheeler AP, Abraham A, Barnes C, Brown Frandsen R, d'Oiron R, Eichler H, Hampton K, López-Jaime FJ, Lyu CJ, Tavares CMM, Nogami K, Sutton C, Windyga J, Zulfikar B, Castaman G. Real-World Unmet Needs of Patients With Haemophilia A and Haemophilia B With or Without Inhibitors: End-of-Study Results From the explorer6 Non-Interventional Study. Haemophilia. 2025 Sep; 31(5):903-911.
-
Chowdary P, Angchaisuksiri P, Apte S, Astermark J, Benson G, Chan AKC, Jiménez Yuste V, Matsushita T, Høgh Nielsen AR, Sathar J, Sutton C, ?aulyte Trakymiene S, Tran H, Villarreal Martinez L, Wheeler AP, Windyga J, Young G, Thaung Zaw JJ, Eichler H. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial. Lancet Haematol. 2024 Dec; 11(12):e891-e904.
-
Han JH, Dupervil B, Mahajerin A, Kulkarni R, Manco-Johnson M, Thornburg C. Clinical and treatment characteristics of infants and toddlers less than 2 years of age with hemophilia. Blood Adv. 2024 06 11; 8(11):2707-2717.
-
Mrakotsky C, Walsh KS, Buranahirun Burns C, Croteau SE, Markert A, Geybels M, Hannemann C, Rajpurkar M, Shapiro KA, Wilkening GN, Ventola P, Cooper DL. The eTHINK Study: Cognitive and Behavioral Outcomes in Children with Hemophilia. J Pediatr. 2024 Sep; 272:114089.
-
Itzler R, Buckner TW, Leebeek FWG, Miller J, Recht M, Drelich D, Monahan PE, Pipe SW. Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE-B trial 2 years after gene therapy. Haemophilia. 2024 May; 30(3):709-719.
-
Zemplenyi A, Leonard J, DiStefano MJ, Anderson KE, Wright GC, Mendola ND, Nair K, McQueen RB. Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid. Pharmacoeconomics. 2024 Mar; 42(3):319-328.
-
Fedewa SA, Buckner TW, Parks SG, Tran DQ, Cafuir L, Antun AG, Mattis S, Kempton CL. Racial and Ethnic Differences in Distress, Depression, and Quality of Life in people with hemophilia. J Racial Ethn Health Disparities. 2024 06; 11(3):1394-1404.
-
Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, Lattimore S, Peerlinck K, Van der Valk P, Coppens M, Kampmann P, Meijer K, O'Connell N, Pasi KJ, Hart DP, Kazmi R, Astermark J, Hermans CRJR, Klamroth R, Lemons R, Visweshwar N, von Drygalski A, Young G, Crary SE, Escobar M, Gomez E, Kruse-Jarres R, Quon DV, Symington E, Wang M, Wheeler AP, Gut R, Liu YP, Dolmetsch RE, Cooper DL, Li Y, Goldstein B, Monahan PE. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. N Engl J Med. 2023 02 23; 388(8):706-718.
-
Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Eichler H, Jiménez-Yuste V, Kavakli K, Matsushita T, Poulsen LH, Wheeler AP, Young G, Zupancic-?alek S, Oldenburg J, Chowdary P. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors. Blood Adv. 2022 06 14; 6(11):3422-3432.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|